Application Note: In Vitro and Ex Vivo Immuno-Oncology Drug Discovery

Discover an integrated, end-to-end I/O platform to accelerate early stage drug development

Assessing immunotherapeutics presents many challenges, right from the earliest stage of drug development. The range of unique and diverse agents, which function via immune system modulation, requires specialized immunology assays to evaluate functional, immunomodulatory, and efficacy effects.

Some specific agent classes, e.g. biological agents, may also be difficult to assess in vitro, as assay conditions lack the heterogeneous components of immune cells found in vivo, and which are needed for complete drug response.

Crown Bioscience provides an integrated, end-to-end in vitro and ex vivo immuno-oncology assessment platform, allowing a one stop service for early stage immunotherapeutic evaluation.

Download This Application Note to Learn About:

• Our core in vitro immuno-oncology phenotyping and profiling platform, which allows full monitoring of the immune system and response to test immunotherapeutics
• A full in vitro/ex vivo functional assay platform, built around antigen presentation and immune system activation, regulation of the tumor environment, and immune cell-mediated cancer cell killing assays to determine all aspects of novel agents’ effects
• How we are advancing immuno-oncology research through the identification and validation of novel I/O targets

Download The Application Note Now!